Upgrade to SI Premium - Free Trial

Gemphire Therapeutics (GEMP) Announces Amended, Restated Gemcabene License Agreement with Pfizer (PFE)

August 6, 2018 4:02 PM
Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Hot Corp. News Trading Halts

Next Articles